TransMedics Group, Inc. (NASDAQ:TMDX) Insider Tamer I. Khayal Sells 63,260 Shares

TransMedics Group, Inc. (NASDAQ:TMDXGet Free Report) insider Tamer I. Khayal sold 63,260 shares of TransMedics Group stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $108.54, for a total value of $6,866,240.40. Following the completion of the transaction, the insider now owns 9,792 shares in the company, valued at $1,062,823.68. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

TransMedics Group Stock Performance

Shares of NASDAQ TMDX opened at $127.99 on Friday. The business’s 50-day simple moving average is $85.54 and its 200-day simple moving average is $76.85. The company has a debt-to-equity ratio of 3.69, a quick ratio of 8.49 and a current ratio of 9.30. TransMedics Group, Inc. has a 52 week low of $36.42 and a 52 week high of $129.66. The firm has a market cap of $4.19 billion, a price-to-earnings ratio of -376.44 and a beta of 1.87.

TransMedics Group (NASDAQ:TMDXGet Free Report) last announced its quarterly earnings results on Tuesday, April 30th. The company reported $0.35 EPS for the quarter, beating the consensus estimate of ($0.05) by $0.40. TransMedics Group had a positive return on equity of 8.29% and a negative net margin of 3.43%. The company had revenue of $96.90 million for the quarter, compared to the consensus estimate of $83.78 million. During the same quarter last year, the company posted ($0.08) earnings per share. The company’s revenue for the quarter was up 132.9% compared to the same quarter last year. As a group, equities research analysts expect that TransMedics Group, Inc. will post 0.54 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Venturi Wealth Management LLC bought a new stake in TransMedics Group during the first quarter valued at about $30,000. Fidelis Capital Partners LLC acquired a new position in shares of TransMedics Group during the 1st quarter worth about $35,000. Cutler Group LLC CA boosted its stake in TransMedics Group by 600.0% during the 3rd quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock valued at $38,000 after purchasing an additional 600 shares during the period. RiverPark Advisors LLC acquired a new stake in TransMedics Group in the 3rd quarter valued at approximately $60,000. Finally, First Horizon Advisors Inc. increased its position in TransMedics Group by 26.8% in the 4th quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock worth $83,000 after buying an additional 222 shares during the period. Institutional investors own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on TMDX shares. Canaccord Genuity Group boosted their price target on shares of TransMedics Group from $102.00 to $117.00 and gave the company a “buy” rating in a report on Wednesday. Oppenheimer increased their price objective on TransMedics Group from $105.00 to $125.00 and gave the stock an “outperform” rating in a research note on Wednesday. TD Cowen lifted their target price on TransMedics Group from $100.00 to $130.00 and gave the company a “buy” rating in a research note on Wednesday. JPMorgan Chase & Co. increased their price target on shares of TransMedics Group from $105.00 to $127.00 and gave the stock an “overweight” rating in a research report on Wednesday. Finally, Morgan Stanley raised their price target on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 28th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to, the stock currently has an average rating of “Moderate Buy” and an average price target of $119.00.

Get Our Latest Stock Analysis on TMDX

About TransMedics Group

(Get Free Report)

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Read More

Insider Buying and Selling by Quarter for TransMedics Group (NASDAQ:TMDX)

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with's FREE daily email newsletter.